Zoetis Inc
NYSE:ZTS

Watchlist Manager
Zoetis Inc Logo
Zoetis Inc
NYSE:ZTS
Watchlist
Price: 173.96 USD -1.24% Market Closed
Market Cap: 78.8B USD
Have any thoughts about
Zoetis Inc?
Write Note

Intrinsic Value

The intrinsic value of one ZTS stock under the Base Case scenario is 122.82 USD. Compared to the current market price of 173.96 USD, Zoetis Inc is Overvalued by 29%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ZTS Intrinsic Value
122.82 USD
Overvaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Zoetis Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ZTS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ZTS?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Pharmaceuticals Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Zoetis Inc

Provide an overview of the primary business activities
of Zoetis Inc.

What unique competitive advantages
does Zoetis Inc hold over its rivals?

What risks and challenges
does Zoetis Inc face in the near future?

Has there been any significant insider trading activity
in Zoetis Inc recently?

Summarize the latest earnings call
of Zoetis Inc.

What significant events have occurred
in Zoetis Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Zoetis Inc.

Provide P/S
for Zoetis Inc.

Provide P/E
for Zoetis Inc.

Provide P/OCF
for Zoetis Inc.

Provide P/FCFE
for Zoetis Inc.

Provide P/B
for Zoetis Inc.

Provide EV/S
for Zoetis Inc.

Provide EV/GP
for Zoetis Inc.

Provide EV/EBITDA
for Zoetis Inc.

Provide EV/EBIT
for Zoetis Inc.

Provide EV/OCF
for Zoetis Inc.

Provide EV/FCFF
for Zoetis Inc.

Provide EV/IC
for Zoetis Inc.

Show me price targets
for Zoetis Inc made by professional analysts.

What are the Revenue projections
for Zoetis Inc?

How accurate were the past Revenue estimates
for Zoetis Inc?

What are the Net Income projections
for Zoetis Inc?

How accurate were the past Net Income estimates
for Zoetis Inc?

What are the EPS projections
for Zoetis Inc?

How accurate were the past EPS estimates
for Zoetis Inc?

What are the EBIT projections
for Zoetis Inc?

How accurate were the past EBIT estimates
for Zoetis Inc?

Compare the revenue forecasts
for Zoetis Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Zoetis Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Zoetis Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Zoetis Inc compared to its peers.

Compare the P/E ratios
of Zoetis Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Zoetis Inc with its peers.

Analyze the financial leverage
of Zoetis Inc compared to its main competitors.

Show all profitability ratios
for Zoetis Inc.

Provide ROE
for Zoetis Inc.

Provide ROA
for Zoetis Inc.

Provide ROIC
for Zoetis Inc.

Provide ROCE
for Zoetis Inc.

Provide Gross Margin
for Zoetis Inc.

Provide Operating Margin
for Zoetis Inc.

Provide Net Margin
for Zoetis Inc.

Provide FCF Margin
for Zoetis Inc.

Show all solvency ratios
for Zoetis Inc.

Provide D/E Ratio
for Zoetis Inc.

Provide D/A Ratio
for Zoetis Inc.

Provide Interest Coverage Ratio
for Zoetis Inc.

Provide Altman Z-Score Ratio
for Zoetis Inc.

Provide Quick Ratio
for Zoetis Inc.

Provide Current Ratio
for Zoetis Inc.

Provide Cash Ratio
for Zoetis Inc.

What is the historical Revenue growth
over the last 5 years for Zoetis Inc?

What is the historical Net Income growth
over the last 5 years for Zoetis Inc?

What is the current Free Cash Flow
of Zoetis Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Zoetis Inc.

Business Breakdown

Zoetis Inc. is a leading global animal health company dedicated to advancing animal care through innovative solutions that enhance the well-being and productivity of livestock and companion animals. Established in 1952 as a former division of the pharmaceutical giant Pfizer, Zoetis transitioned into its standalone identity in 2013 and has since carved out a significant niche in the growing market for animal health products. With a diverse portfolio that includes vaccines, parasiticides, and diagnostic tools, the company serves farmers, veterinarians, and pet owners, contributing to the health of food-producing animals and pets alike. The robust demand for high-quality animal health products—...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Zoetis Inc

Current Assets 6.3B
Cash & Short-Term Investments 1.7B
Receivables 1.4B
Other Current Assets 3.2B
Non-Current Assets 8.1B
PP&E 3.5B
Intangibles 3.9B
Other Non-Current Assets 624m
Current Liabilities 1.7B
Accounts Payable 404m
Accrued Liabilities 1.1B
Other Current Liabilities 238m
Non-Current Liabilities 7.4B
Long-Term Debt 6.6B
Other Non-Current Liabilities 847m
Efficiency

Earnings Waterfall
Zoetis Inc

Revenue
9.2B USD
Cost of Revenue
-2.7B USD
Gross Profit
6.4B USD
Operating Expenses
-3.1B USD
Operating Income
3.3B USD
Other Expenses
-907m USD
Net Income
2.4B USD

Free Cash Flow Analysis
Zoetis Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Zoetis achieved a robust 14% operational revenue growth in Q3 2024, driven by a 15% increase in U.S. sales and a 13% rise internationally. Key products like Librela generated impressive sales, growing 97% year-over-year. The company raised its full-year revenue guidance to between $9.2 billion and $9.3 billion, reflecting a 10% to 11% operational growth. Adjusted net income is expected between $2.67 billion and $2.695 billion, with a projected 13.5% to 14.5% operational growth. Looking ahead, while Q4 may see a slowdown due to recent divestitures, long-term growth remains strong with expanding markets in osteoarthritis treatments and continued innovation.

What is Earnings Call?
Fundamental Scores

ZTS Profitability Score
Profitability Due Diligence

Zoetis Inc's profitability score is 75/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Positive Free Cash Flow
Exceptional ROE
75/100
Profitability
Score

Zoetis Inc's profitability score is 75/100. The higher the profitability score, the more profitable the company is.

ZTS Solvency Score
Solvency Due Diligence

Zoetis Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
High Interest Coverage
Long-Term Solvency
65/100
Solvency
Score

Zoetis Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ZTS Price Targets Summary
Zoetis Inc

Wall Street analysts forecast ZTS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZTS is 222.96 USD with a low forecast of 173.84 USD and a high forecast of 260.4 USD.

Lowest
Price Target
173.84 USD
0% Downside
Average
Price Target
222.96 USD
28% Upside
Highest
Price Target
260.4 USD
50% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ZTS?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for ZTS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ZTS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

ZTS News

Other Videos

Profile

Zoetis Inc Logo
Zoetis Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

78.6B USD

Dividend Yield

0.99%

Description

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The company is headquartered in Parsippany, New Jersey and currently employs 12,100 full-time employees. The company went IPO on 2013-02-01. The firm has a business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within product categories such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The firm operate its business through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers. The firm market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and its products are sold in more than 100 countries.

Contact

NEW JERSEY
Parsippany
10 Sylvan Way
+19738227000.0
www.zoetis.com

IPO

2013-02-01

Employees

12 100

Officers

CEO & Director
Ms. Kristin C. Peck
Executive VP & CFO
Mr. Wetteny N. Joseph
EVP, Chief Digital & Tech. Officer, Group President for China, Brazil and Preci. Animal Health
Ms. Wafaa Mamilli
Executive VP and President of Research & Development
Dr. Robert J. Polzer Ph.D.
Vice President of Investor Relations
Mr. Steven Frank
Executive VP, General Counsel & Corporate Secretary
Ms. Roxanne Lagano
Show More
VP & Chief Communications Officer
Mr. William Price
Executive VP, Chief Human Resources Officer & Global Operations
Ms. Julie A. Fuller
Executive VP of Corporate Affairs & Communications and Chief Sustainability Officer
Ms. Jeannette Ferran Astorga
Executive VP and President of Global Manufacturing & Supply
Mr. Nick Ashton
Show Less

See Also

Discover More
What is the Intrinsic Value of one ZTS stock?

The intrinsic value of one ZTS stock under the Base Case scenario is 122.82 USD.

Is ZTS stock undervalued or overvalued?

Compared to the current market price of 173.96 USD, Zoetis Inc is Overvalued by 29%.

Back to Top